Press release
Hypertriglyceridemia: Clinical Landscape, Companies, Therapeutic Assessment, Treatment Algorithm, and Pipeline Insights | Key Players: NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer B
Hypertriglyceridemia Clinical Landscape
According to DelveInsight, the Hypertriglyceridemia pipeline features 18+ key pharmaceutical companies actively developing over 20 therapeutic candidates targeting this condition.
Overview of Hypertriglyceridemia
Hypertriglyceridemia refers to a metabolic disorder characterized by elevated triglyceride levels in the bloodstream, which significantly increases the risk of cardiovascular diseases (CVD) and acute pancreatitis. The condition is often associated with uncontrolled diabetes, obesity, sedentary lifestyles, and genetic predispositions.
Typically, hypertriglyceridemia remains asymptomatic until triglyceride concentrations exceed 1,000-2,000 mg/dL, at which point serious complications such as pancreatitis and metabolic disturbances may develop.
Management strategies primarily emphasize lifestyle modifications-including dietary changes, weight management, and regular physical activity-and may be complemented by pharmacological interventions such as statins, fibrates, or omega-3 fatty acids when necessary. In addition, addressing underlying medical conditions is crucial to achieving optimal lipid control and minimizing cardiovascular risk.
Request for a detailed insights report on Hypertriglyceridemia pipeline insights [https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
DelveInsight's "Hypertriglyceridemia Pipeline Insight 2025" report offers an in-depth evaluation of the current clinical development landscape and emerging growth opportunities within the Hypertriglyceridemia therapeutics market.
Key Takeaways from the Hypertriglyceridemia Pipeline Report
*
DelveInsight's Hypertriglyceridemia Pipeline Report highlights a dynamic and competitive landscape, featuring over 18 active companies engaged in the development of more than 20 investigational therapies for the treatment of Hypertriglyceridemia.
*
In December 2024, the FDA approved Tryngolza (olezarsen) as the first-ever therapy for familial chylomicronemia syndrome (FCS)-a rare and severe subtype of hypertriglyceridemia. Additionally, Arrowhead Pharmaceuticals' plozasiran had its New Drug Application (NDA) accepted by the FDA in January 2025, with a PDUFA decision date scheduled for November 18, 2025.
*
Leading companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, Inc., GeneCradle, MediciNova, and Regeneron Pharmaceuticals are actively working to advance novel therapeutic candidates aimed at enhancing the treatment landscape for hypertriglyceridemia.
*
Among the promising therapies currently under development are SEFA-1024, DR10624, GC304, and several others, spanning multiple stages of clinical research and showing potential to significantly improve disease management outcomes.
Hypertriglyceridemia Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Hypertriglyceridemia Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertriglyceridemia market.
Download our free sample page report on Hypertriglyceridemia pipeline insights [https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hypertriglyceridemia Emerging Drugs
SEFA-1024 - NorthSea Therapeutics
SEFA-1024 is an oral, gut- and liver-targeted semi-synthetic derivative of eicosapentaenoic acid being developed for the treatment of severe hypertriglyceridemia (sHTG)-a condition that significantly elevates the risk of acute pancreatitis and may contribute to cardiovascular complications. Existing treatment options often have limited effectiveness in reducing triglycerides (TG) and non-HDL cholesterol or improving glycemic control, highlighting a substantial unmet clinical need. Supported by promising preclinical results from a human-relevant HTG model, SEFA-1024 demonstrates potential to fill these gaps and is currently undergoing Phase II clinical evaluation for hypertriglyceridemia.
DR10624 - Doer Biologics
DR10624 is a first-in-class, long-acting tri-agonist that simultaneously targets FGF21R, GLP-1R, and the glucagon receptor (GCGR). Developed through Doer Bio's proprietary MultipleBody platform, it is engineered to provide balanced activity for effective metabolic disease management. Preclinical studies have demonstrated that DR10624 can significantly reduce body weight, lower triglyceride levels, normalize lipid profiles, and enhance liver function. The candidate is currently being evaluated in Phase II clinical trials for the treatment of severe hypertriglyceridemia.
Hypertriglyceridemia Companies
Approximately 18 or more major companies are currently engaged in developing therapies for hypertriglyceridemia, with NorthSea Therapeutics being one of the leading players, having its drug candidates in the most advanced Phase II stage of development.
DelveInsight's report covers around 75+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Hypertriglyceridemia Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hypertriglyceridemia Therapies and Key Companies: Hypertriglyceridemia Clinical Trials and advancements [https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hypertriglyceridemia Pipeline Therapeutic Assessment
- Hypertriglyceridemia Assessment by Product Type
- Hypertriglyceridemia By Stage
- Hypertriglyceridemia Assessment by Route of Administration
- Hypertriglyceridemia Assessment by Molecule Type
Download Hypertriglyceridemia Sample report to know in detail about the Hypertriglyceridemia treatment market @ Hypertriglyceridemia Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertriglyceridemia-clinical-landscape-companies-therapeutic-assessment-treatment-algorithm-and-pipeline-insights-key-players-northsea-therapeutics-arrowhead-pharmaceuticals-zhejiang-doer-b]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertriglyceridemia: Clinical Landscape, Companies, Therapeutic Assessment, Treatment Algorithm, and Pipeline Insights | Key Players: NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer B here
News-ID: 4251685 • Views: …
More Releases from ABNewswire
Atopic Dermatitis Clinical, Companies, Therapeutic Assessment, Therapies, Treatm …
DelveInsight's, "Atopic Dermatitis - Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's analysis indicates that the Atopic Dermatitis (AD) pipeline includes…
Electrical Stimulation Devices Market Set for Consistent Expansion Driven by Tec …
Electrical Stimulation Devices Market By Product Type (Wired Devices And Wireless Devices), By Indication (Neurological Disorders, Pain Management, Musculoskeletal Disorders, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, And Others), by geography, is projected to grow at a noteworthy CAGR forecast till 2030 owing to the rising prevalence of musculoskeletal disorders and technological innovation in product development
The global functional electrical stimulation (FES) devices market is expected to expand…
Brain Monitoring Devices Market Set for Consistent Expansion Driven by Technolog …
Brain Monitoring Devices market is expected to rise in the upcoming years owing to various factors during the study period, estimates DelveInsight.
The global brain monitoring devices market, estimated at USD 5.89 billion in 2023, is expected to grow at a CAGR of 7.27% from 2024 to 2030, reaching approximately USD 9.13 billion by 2030. This growth is primarily attributed to the rising incidence of neurological conditions such as multiple sclerosis,…
Sleep Apnea Devices Market Set for Consistent Expansion Driven by Technological …
The global sleep apnea devices market is growing at a CAGR of 6.58% during the forecast period from 2025 to 2032.
The global sleep apnea devices market, estimated at USD 7.53 billion in 2023, is anticipated to expand at a CAGR of 6.26% between 2024 and 2030, reaching approximately USD 10.82 billion by 2030. This growth is primarily attributed to the increasing prevalence of sleep apnea, rising obesity levels, and accelerating…
More Releases for Hypertriglyceridemia
Hypertriglyceridemia Market is expected to reach USD 39 billion by 2034
Hypertriglyceridemia is a common lipid disorder characterized by elevated levels of triglycerides in the blood, often associated with obesity, diabetes, metabolic syndrome, and genetic predisposition. While mild to moderate hypertriglyceridemia is widespread, severe cases can lead to acute pancreatitis, cardiovascular disease, and liver complications. The condition is both a standalone metabolic issue and a risk factor for a broader spectrum of chronic diseases.
Download Full PDF Sample Copy of Market Report…
Severe Hypertriglyceridemia Market is expected to reach USD 8.9 billion by 2034
Severe hypertriglyceridemia, defined by triglyceride levels exceeding 500 mg/dL, is a serious metabolic condition linked to an elevated risk of cardiovascular disease, pancreatitis, and liver complications. As obesity, sedentary lifestyles, and diabetes become more prevalent worldwide, the burden of hypertriglyceridemia is rising rapidly. This has created a significant demand for effective pharmacological treatments, dietary interventions, and lifestyle management solutions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72003
According to Exactitude…
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe…
Hypertriglyceridemia Therapeutics Market Detailed In New Research Report 2024 |S …
The most recent report published by CMI indicates that the "Hypertriglyceridemia Therapeutics Market 2024-2031" is likely to accelerate significantly in the next few years. The Hypertriglyceridemia Therapeutics Market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The Hypertriglyceridemia Therapeutics Market study includes information on market factors such as the market dynamics, drivers, restraints,…
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
